The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Pyzchiva( formerly SB 17), intended for the treatment of plaque psoriasis, including paediatric plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease in adults. The applicant for this medicinal product is Samsung Bioepis NL B.V.
Janssen has announced results from a post-hoc analysis which showed that at 52 weeks, Invokana (canagliflozin) provided reductions in both...
Hidradenitis suppurativa (HS) is a chronic, recurring, debilitating inflammatory skin disease, which mainly affects the inverse areas of the body leading to scarring and disfigurement.
Zostavax is a live-attenuated varicella zoster virus (VZV) vaccine recommended for use in adults >50 years of age to prevent shingles. The main risk factor for the development of shingles is age, which correlates with decreasing cell-mediated immunity.
Merck Inc announced the European Medicines Agency has accepted for review a marketing authorization application for grazoprevir/elbasvir (100mg/50mg), an investigational,...
Tivozanib is a tyrosine kinase inhibitor that targets all vascular endothelial growth factor receptors (VEGFRs), causing inhibition of angiogenesis. It has recently been approved by the European Medicines Agency (EMA)...
The National Institute for Health and Care Excellence (NICE) in the UK has published a positive draft final appraisal determination...
Hidradenitis suppurativa (HS) is an inflammatory, debilitating follicular skin disease with recurring flare-ups.
Merck has announced that the company has submitted a New Drug Application to the FDA for grazoprevir/elbasvir (100mg/50mg), an investigational...
Gilead Sciences announced that the European Commission has granted marketing authorization for Vosevi (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg), as a once-daily...